 SEATTLE, July 07, 2021 GLOBE NEWSWIRE -- Impel NeuroPharma, Inc. Impel, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system CNS diseases with high unmet medical needs, today announced the closing of a 50 million debt facility with Oxford Finance LLC and Silicon Valley Bank, of which the first 20 million was funded at closing. 